TY - JOUR
T1 - Pharmacokinetics of indomethacin in pregnancy
AU - Rytting, Erik
AU - Nanovskaya, Tatiana N.
AU - Wang, Xiaoming
AU - Vernikovskaya, Daria I.
AU - Clark, Shannon M.
AU - Cochran, Marlo
AU - Abdel-Rahman, Susan M.
AU - Venkataramanan, Raman
AU - Caritis, Steve N.
AU - Hankins, Gary
AU - Ahmed, Mahmoud
N1 - Funding Information:
Acknowledgments This work was supported by grant U10HD047891 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Obstetrical Pharmacology Research Units Network (OPRU), to G.D.V. Hankins. The authors sincerely appreciate the support of the physicians and nurses of the Labor and Delivery Ward at John Sealy Hospital, the teaching hospital at the University of Texas Medical Branch, Galveston, Texas, nursing coordinator Aimee Jackson, and the Perinatal Research Division of the Department of Obstetrics and Gynecology. Dawn Fischer, RN, from the Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh, is also thanked for her assistance. Erik Rytting, Tatiana N. Nanovskaya, Xiaoming Wang, Daria I. Vernikovskaya, Shannon M. Clark, Marlo Cochran, Susan M. Abdel-Rahman, Raman Venkataramanan, Steve N. Caritis, Gary D.V. Hankins, and Mahmoud S. Ahmed have no conflicts of interest to declare.
PY - 2014/6
Y1 - 2014/6
N2 - Background and objectives: Although indomethacin has been widely used for the treatment of preterm labor over the past 40 years, there are few reports regarding its pharmacokinetics in pregnant women. Methods: This opportunistic study assessed the steady-state pharmacokinetics of indomethacin in pregnant subjects to whom an oral dose of 25 mg every 6 h was prescribed. Indomethacin concentrations in plasma and urine were analyzed by a validated high-performance liquid chromatography method with mass spectrometric detection. Results: The mean area under the plasma concentration versus time curve at steady state (AUCss) was 1.91 ± 0.53 μg·h/mL, mean peak plasma concentration (C max) was 1.02 ± 0.49 μg/mL, and mean time to reach C max (t max) was 1.3 ± 0.7 h. The mean apparent clearance at steady state was 14.5 ± 5.5 L/h, which is higher than the apparent clearance reported in the literature for non-pregnant subjects. Indomethacin crosses the placenta; the mean fetal/maternal ratio from five sets of cord blood samples collected at delivery was 4.0 ± 1.1. Conclusions: Further studies are needed to determine whether any dose adjustments are necessary as a result of the increased clearance of indomethacin during pregnancy.
AB - Background and objectives: Although indomethacin has been widely used for the treatment of preterm labor over the past 40 years, there are few reports regarding its pharmacokinetics in pregnant women. Methods: This opportunistic study assessed the steady-state pharmacokinetics of indomethacin in pregnant subjects to whom an oral dose of 25 mg every 6 h was prescribed. Indomethacin concentrations in plasma and urine were analyzed by a validated high-performance liquid chromatography method with mass spectrometric detection. Results: The mean area under the plasma concentration versus time curve at steady state (AUCss) was 1.91 ± 0.53 μg·h/mL, mean peak plasma concentration (C max) was 1.02 ± 0.49 μg/mL, and mean time to reach C max (t max) was 1.3 ± 0.7 h. The mean apparent clearance at steady state was 14.5 ± 5.5 L/h, which is higher than the apparent clearance reported in the literature for non-pregnant subjects. Indomethacin crosses the placenta; the mean fetal/maternal ratio from five sets of cord blood samples collected at delivery was 4.0 ± 1.1. Conclusions: Further studies are needed to determine whether any dose adjustments are necessary as a result of the increased clearance of indomethacin during pregnancy.
UR - http://www.scopus.com/inward/record.url?scp=84903723035&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84903723035&partnerID=8YFLogxK
U2 - 10.1007/s40262-014-0133-6
DO - 10.1007/s40262-014-0133-6
M3 - Article
C2 - 24493205
AN - SCOPUS:84903723035
SN - 0312-5963
VL - 53
SP - 545
EP - 551
JO - Clinical Pharmacokinetics
JF - Clinical Pharmacokinetics
IS - 6
ER -